Kither Biotech concludes Phase I study of KIT2014

Kither Biotech has completed its Phase I clinical trial assessing KIT2014, an inhaled peptide therapy designed for the treatment of respiratory diseases. The study included SAD and MAD components to assess KIT2014’s safety and tolerability, as well as monitor plasma pharmacokinetics. KIT2014 is a cell-permeable inhaled peptide that inhibits PDE3/4, increasing cAMP for bronchodilation and anti-inflammation. Credit: NMK-Studio / Shutterstock.com. Kither Biotech has completed its Phase I clinical trial assessing KIT2014, an inhaled peptide therapy designed for the treatment of respiratory diseases. The randomised, double-blind, two-part dose-escalation, placebo-controlled trial assessed KIT2014 in 56 healthy participants. LOA and PTSR Model -…

Source: Clinical Trials Arena